SIX · ROP.SW
Roche Holding AG
CHF 403.70+CHF 2.00 (+0.5%)
Roche Holding AG’s quoted price sits in the upper half of its reported 52-week range, 0.54% below the high.
Loading market information…
JPX · 4519.T · JPY
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 06:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · JPY. Historical prices are not a forecast.
Chugai Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 36.24% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Chugai Pharmaceutical Co., Ltd.’s forward annual dividend is ¥66 per share, paid annual. The forward yield is 0.97% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Chugai Pharmaceutical Co., Ltd.’s next earnings report is currently expected on Feb 4, 2027, with estimated earnings per share of ¥78. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Chugai Pharmaceutical Co., Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Chugai Pharmaceutical Co., Ltd. is a prominent global pharmaceutical company, operating subsidiaries involved in the full lifecycle of drug development, from research and manufacturing to sales, import, and export, serving both Japanese and international markets. Its commercialized product portfolio spans several key therapeutic areas. These include a robust oncology offering with leading treatments like Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda. Additionally, it provides medications for bone health (e.g., Actemra, Edirol, Bonviva), renal conditions (such as Mircera and Oxarol), and neurological or other diverse ailments (including Hemlibra, CellCept, and Enspryng). Beyond its existing offerings, the company maintains an active research and development pipeline. This pipeline features multiple promising candidates targeting oncology, orthopedic and joint disorders, autoimmune diseases, kidney-related conditions, and various neurological or other health issues. Strategic partnerships are central to Chugai's operations, most notably a significant alliance with the Roche Group. The company also fosters collaborative research initiatives with academic institutions. Established in 1925, Chugai's headquarters are located in Tokyo, Japan, and it operates as a key subsidiary of Roche Holding Ltd.
Latest available per-share figures in JPY. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:34 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q2 2025 | Jul 24, 2025 | ¥59-21.95% vs estimate | ¥290.01B-10.75% vs estimate |
|---|
| Q1 2025 | Apr 24, 2025 | ¥57+15.96% vs estimate | ¥288.46B+13.57% vs estimate |
|---|
| Q4 2024 | Jan 30, 2025 | ¥55-3.06% vs estimate | ¥300.6B+4.69% vs estimate |
|---|
KEEP COMPARING
CHF 403.70+CHF 2.00 (+0.5%)
Roche Holding AG’s quoted price sits in the upper half of its reported 52-week range, 0.54% below the high.
£135.70+£5.18 (+3.97%)
AstraZeneca PLC’s quoted price sits in the upper half of its reported 52-week range, 13.74% below the high.
¥6,651+¥180 (+2.78%)
Takeda Pharmaceutical Company Limited’s quoted price sits in the upper half of its reported 52-week range, 0.91% below the high.
¥12,015-¥270 (-2.2%)
Otsuka Holdings Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 6.1% below the high.
¥2,754+¥137 (+5.21%)
Daiichi Sankyo Company, Limited’s quoted price sits in the lower half of its reported 52-week range, 30.19% below the high.
¥2,571+¥58 (+2.31%)
Astellas Pharma Inc.’s quoted price sits in the upper half of its reported 52-week range, 5.37% below the high.
¥3,012+¥23 (+0.77%)
Shionogi & Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 19.85% below the high.
¥5,052+¥78 (+1.57%)
Eisai Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 3.64% below the high.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
